Top-Rated StocksTop-RatedPositive News SentimentPositive NewsNASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis $3.56 -0.10 (-2.60%) As of 12:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Biomea Fusion Stock (NASDAQ:BMEA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biomea Fusion alerts:Sign Up Key Stats Today's Range$3.54▼$3.7350-Day Range$3.48▼$5.8552-Week Range$3.25▼$19.35Volume144,623 shsAverage Volume604,095 shsMarket Capitalization$128.83 millionP/E RatioN/ADividend YieldN/APrice Target$39.36Consensus RatingBuy Company OverviewBiomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Read More… Biomea Fusion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreBMEA MarketRank™: Biomea Fusion scored higher than 68% of companies evaluated by MarketBeat, and ranked 332nd out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiomea Fusion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageBiomea Fusion has only been the subject of 2 research reports in the past 90 days.Read more about Biomea Fusion's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biomea Fusion are expected to grow in the coming year, from ($3.93) to ($3.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Biomea Fusion's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted33.92% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 12.62%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted33.92% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 12.62%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentBiomea Fusion has a news sentiment score of 1.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biomea Fusion this week, compared to 3 articles on an average week.Search InterestOnly 13 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -31% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders27.57% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biomea Fusion's insider trading history. Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Email Address BMEA Stock News HeadlinesBiomea Fusion, Inc. (NASDAQ:BMEA) is a favorite amongst institutional investors who own 51%February 6, 2025 | finance.yahoo.comBiomea Fusion’s Strategic Focus on Metabolic Diseases and Promising Pipeline Advances Garner Buy RatingJanuary 14, 2025 | markets.businessinsider.com70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.February 21, 2025 | WealthPress (Ad)Biomea Fusion to become diabetes, obesity medicines companyJanuary 13, 2025 | markets.businessinsider.comBiomea Fusion price target lowered to $16 from $128 at D. Boral CapitalJanuary 13, 2025 | markets.businessinsider.comBiomea Fusion to Become a Diabetes & Obesity Medicines CompanyJanuary 13, 2025 | markets.businessinsider.comScotiabank Sticks to Its Buy Rating for Biomea Fusion (BMEA)January 8, 2025 | markets.businessinsider.comBiomea Fusion reports new preclinical data on icovamenib-semaglutide studyJanuary 8, 2025 | markets.businessinsider.comSee More Headlines BMEA Stock Analysis - Frequently Asked Questions How have BMEA shares performed this year? Biomea Fusion's stock was trading at $3.88 on January 1st, 2025. Since then, BMEA stock has decreased by 8.6% and is now trading at $3.5450. View the best growth stocks for 2025 here. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) announced its earnings results on Tuesday, October, 29th. The company reported ($0.91) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.03. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Biomea Fusion's major shareholders? Biomea Fusion's top institutional shareholders include Baker BROS. Advisors LP (4.01%), Rosalind Advisors Inc., Two Sigma Investments LP (1.55%) and Adage Capital Partners GP L.L.C. (1.38%). Insiders that own company stock include Bihua Chen, A2a Pharmaceuticals, Inc and Michael JM Hitchcock. View institutional ownership trends. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomea Fusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomea Fusion investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings10/29/2024Today2/21/2025Next Earnings (Estimated)4/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMEA CUSIPN/A CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$39.36 High Stock Price Target$128.00 Low Stock Price Target$11.00 Potential Upside/Downside+978.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($4.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-118.90% Return on Assets-93.66% Debt Debt-to-Equity RatioN/A Current Ratio3.39 Quick Ratio3.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book0.77Miscellaneous Outstanding Shares36,240,000Free Float26,248,000Market Cap$132.28 million OptionableOptionable Beta-0.34 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:BMEA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.